A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

Carlos Gomez-Martín; Fernando Lopez-Rios; Jorge Aparicio; Jorge Barriuso; Rocio García-Carbonero; Roberto Pazo; Fernando Rivera; Mercedes Salgado; Antonieta Salud; Enrique Vázquez-Sequeiros; Florian Lordick

doi:10.1016/j.canlet.2014.05.019

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

Carlos Gomez-Martín, Fernando Lopez-Rios, Jorge Aparicio, Jorge Barriuso, Rocio García-Carbonero, Roberto Pazo, Fernando Rivera, Mercedes Salgado, Antonieta Salud, Enrique Vázquez-Sequeiros, Florian Lordick

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Review article › peer-review

Abstract

Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies.

Original language	English
Pages (from-to)	30-40
Number of pages	11
Journal	Cancer Letters
Volume	351
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2014.05.019
Publication status	Published - 28 Aug 2014

Keywords

Adenocarcinoma/drug therapy
Animals
Antibodies, Monoclonal, Humanized/therapeutic use
Antineoplastic Agents/therapeutic use
Biomarkers, Tumor/metabolism
Clinical Trials as Topic
Humans
Prognosis
Receptor, ErbB-2/metabolism
Stomach Neoplasms/drug therapy
Trastuzumab

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2014.05.019

Cite this

@article{4d9f898af4c242ea9286fe296ca60c7d,

title = "A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond",

abstract = "Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies.",

keywords = "Adenocarcinoma/drug therapy, Animals, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Agents/therapeutic use, Biomarkers, Tumor/metabolism, Clinical Trials as Topic, Humans, Prognosis, Receptor, ErbB-2/metabolism, Stomach Neoplasms/drug therapy, Trastuzumab",

author = "Carlos Gomez-Mart{\'i}n and Fernando Lopez-Rios and Jorge Aparicio and Jorge Barriuso and Rocio Garc{\'i}a-Carbonero and Roberto Pazo and Fernando Rivera and Mercedes Salgado and Antonieta Salud and Enrique V{\'a}zquez-Sequeiros and Florian Lordick",

year = "2014",

month = aug,

day = "28",

doi = "10.1016/j.canlet.2014.05.019",

language = "English",

volume = "351",

pages = "30--40",

journal = "Cancer Letters",

issn = "1872-7980",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - A critical review of HER2-positive gastric cancer evaluation and treatment

T2 - from trastuzumab, and beyond

AU - Gomez-Martín, Carlos

AU - Lopez-Rios, Fernando

AU - Aparicio, Jorge

AU - Barriuso, Jorge

AU - García-Carbonero, Rocio

AU - Pazo, Roberto

AU - Rivera, Fernando

AU - Salgado, Mercedes

AU - Salud, Antonieta

AU - Vázquez-Sequeiros, Enrique

AU - Lordick, Florian

PY - 2014/8/28

Y1 - 2014/8/28

N2 - Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies.

AB - Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies.

KW - Adenocarcinoma/drug therapy

KW - Animals

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Antineoplastic Agents/therapeutic use

KW - Biomarkers, Tumor/metabolism

KW - Clinical Trials as Topic

KW - Humans

KW - Prognosis

KW - Receptor, ErbB-2/metabolism

KW - Stomach Neoplasms/drug therapy

KW - Trastuzumab

U2 - 10.1016/j.canlet.2014.05.019

DO - 10.1016/j.canlet.2014.05.019

M3 - Review article

C2 - 24943493

SN - 1872-7980

VL - 351

SP - 30

EP - 40

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this